Optimer Antibiotic Gets Panel Nod, CareFusion Buys Vestara, Tracon Raises $16.5M, & More San Diego Life Sciences News
(Page 2 of 2)
antibiotics as part of World Health Day.
—San Diego-based CareFusion (NYSE: CFN) paid $17 million to acquire Irvine, CA-based Vestara and the technology it developed to help hospitals safely dispose of pharmaceuticals. Vestara’s software uses bar codes to cross-reference drugs to obtain information about federal, state and local laws regarding their disposal.
—La Jolla Pharmaceutical said it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands (RILs) from privately held GliaMed, and plans to focus its resources on this emerging field of regenerative medicine. The biotech says RILs are small-molecule compounds that could be used to promote the regeneration of a wide range of tissues, including complex skin tissue, lung tissue, cardiac muscle, cartilage, and bone, following acute injury. Financial terms were not disclosed.
—Several local life sciences companies participated in funding deals over the past week, following what seems like a prolonged drought in the sector. They were:
—Tracon Pharmaceuticals, which has been licensing and developing drugs for cancer and age-related macular degeneration, raised $16.5 million of a planned $24.5 million equity round. The company declined to comment on the report.
—San Diego-based Biotix, which provides pipette tips and other lab supplies, raised $2 million out of a planned $4 million round of equity funding. A spokeswoman told me Biotix has raised a total of $74 million since it was established in the 2005 merger of Continental Lab Products and a predecessor startup.
—AnaBios, a San Diego contract research organization that specializes in assessing drug safety and efficacy, raised $800,000 of a planned $2 million round led by Southern California’s Tech Coast Angels.